A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

Clinical Trial of an Omicron-Targeting Vaccine Is Ready to Begin


As Americans’ COVID-19 fatigue continues to grow, Pfizer announced it will begin a clinical trial on a COVID-19 vaccine designed to target the highly transmissible Omicron variant of SARS-CoV-2. Pfizer’s original two-dose COVID-19 vaccine has not been as effective as preventing infection with the Omicron variant as it was against the Delta variant. The trial, conducted in the United States, will test a three-dose regimen on volunteers who are unvaccinated and a third dose among those who have already completed the initial two-dose regimen. For those who have already received a booster shot of the Pfizer series, the effectiveness of a fourth booster will also be evaluated. The trial will include 1,400 participants. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy